David M. Spencer
Plus aucun poste en cours
Profil
David M.
Spencer was the founder of Bellicum Pharmaceuticals, Inc. founded in 2004, where he held the title of Chief Technology Officer from 2018 to 2019.
He also held the position of Professor and Vice Chairman-Pathology & Immunology at Baylor College of Medicine and was the Director & Chief Scientific Officer at Kiromic Biopharma, Inc. Dr. Spencer earned a doctorate degree from the Massachusetts Institute of Technology and an undergraduate degree from the University of California San Diego.
Anciens postes connus de David M. Spencer
| Sociétés | Poste | Fin |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Fondateur | 01/03/2019 |
| KIROMIC BIOPHARMA, INC. | Directeur Technique/Scientifique/R&D | - |
| Baylor College of Medicine | Corporate Officer/Principal | - |
Formation de David M. Spencer
| Massachusetts Institute of Technology | Doctorate Degree |
| University of California San Diego | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| KIROMIC BIOPHARMA, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
